Key facts
- This page summarizes Jason Ehrlich's Form 4 filing for Kodiak Sciences Inc. (KOD).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 13 Aug 2021, 18:45.
Jason Ehrlich - 12 Aug 2021 Form 4 Insider Report for Kodiak Sciences Inc. (KOD)
- Reporting relationship
- Chief Medical Officer and Chief Development Officer
- Issuer ticker
- KOD
- Reported as of
- 12 Aug 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 13 Aug 2021, 18:45:35 UTC
- Prior SEC filing
- 22 Jul 2021
- Next SEC filing
- 24 Aug 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ David Peinsipp, Attorney-in-Fact for Jason Ehrlich
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jason Ehrlich filed Form 4 for Kodiak Sciences Inc. (KOD) on 13 Aug 2021.
Change
- Previous filing in this sequence was filed on 22 Jul 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
KOD
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +50,000
- Change %
- Price
- $0.000000
- Shares after
- 50,000
- Date
- 12 Aug 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,000
- Exercise price
- $88.21
- Footnotes
- F1
KOD
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +15,000
- Change %
- Price
- $0.000000
- Shares after
- 15,000
- Date
- 12 Aug 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,000
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
One-forty-eighth (1/48th) of the shares vest one month after the Vesting Commencement Date (June 30, 2021); the balance of the shares vest in a series of forty-seven (47) successive equal monthly installments measured from the first month anniversary of the Vesting Commencement Date, subject to the Reporting Person's status as a Service Provider (as defined in the 2018 Equity Incentive Plan) on each vesting date.
Footnote F2
Each restricted stock unit represents a contingent right to receive one (1) share of the Issuer's common stock.
Footnote F3
One-fourth (1/4th) of the restricted stock units vest on each of the first four anniversaries of June 15, 2021, subject to the Reporting Person's status as a Service Provider (as defined in the 2018 Equity Incentive Plan) on each vesting date.
SEC remarks
Chief Medical Officer and Chief Development Officer